Merck lays off its simian staff as the industry moves away from chimp research

Merck ($MRK) has added its name to the growing list of entities pulling the plug on chimpanzee research, folding to activist pressure and dismissing its primate subjects once and for all. Merck was among the industry's last holdouts, according to the Humane Society, now joining GlaxoSmithKline ($GSK), Gilead Sciences ($GILD), Novo Nordisk ($NVO) and others in sparing chimps from biomedical research. The drugmaker's decision comes after the National Institutes of Health announced it would retire its more than 300 primates last year, which Director Francis Collins said was simply "the right thing to do." Story (sub. req.)

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.